From the point of view of clinical significance we have shown here that a high expression of SPIB and low expression BATF mRNA can identify a good prognostic group of DLBCL when treated with currently standard immunochemotherapy, R-CHOP. The gene discussed is SPIB; the disease is diffuse large B-cell lymphoma.